Oncology

As Corrixr's novel CRISPR therapy nears human trials, the appointment of Seagen veteran Nancy Whiting signals a strategic shift from lab to market.

Kura Oncology's upcoming kidney cancer data is just the tip of the iceberg. A closer look reveals a strategic play to make darlifarnib a universal partner drug.

Landmark Phase 3 data for HBI-8000 not only offers new hope for melanoma patients but validates a powerful "China-to-global" drug development strategy.

Erasca secures $550M to advance its attack on the notorious RAS/MAPK pathway. A look at the science, the strategy, and what it means for oncology.

Elephas Biosciences adds legendary oncologist Dr. Skip Burris to its board, a pivotal move to commercialize a platform that predicts immunotherapy success.

As corporate consolidation swallows local clinics, a new nonprofit network offers a lifeline to keep cancer care independent, accessible, and human-centered.

A new nonprofit is using tax-exempt bonds to fight healthcare consolidation. Is Anoma Cancer Collective's model a lifeline for local cancer care?

With a new name and $35M in fresh funding, Allotera Therapeutics is doubling down on a pivotal trial for Sofi-cel, a therapy aimed at solving a tough T-cell cancer.

GeneCentric's ExpressCT Rewind™ uses fragmentomics to mine gene expression data from old liquid biopsies, offering a cost-effective way to find new biomarkers.

With bladder cancer recurrence rates stubbornly high, UroGen Pharma is advancing a novel oncolytic virus into human trials. Can it finally break the cycle?

Preclinical data shows GLIX1 can make PARP inhibitors effective in previously unresponsive tumors, a potential game-changer for 50% of ovarian cancer patients.

Avacta taps veteran dealmaker Dr. Patrick Vink as it nears a pivotal data reveal for its pre|CISION® platform, signaling a shift from R&D to high-stakes commercial strategy.

With the appointment of Vita S. Salsman, Immunocine signals a major push to translate its unique "Double Loaded" dendritic cell therapy from lab to clinic.

WellSpan Health's integration with a top local oncology practice promises better care through tech and scale. But does this move signal a brighter future for patients or a troubling trend of market consolidation?

Vivos Inc. wins FDA approval for a human trial of RadioGel®, a targeted therapy that could offer new hope for patients with non-resectable thyroid cancer.

IceCure's ProSense™ is reshaping oncology in Brazil. A US FDA approval provided a critical tailwind, validating a less invasive future for cancer care.

VERAXA Biotech is betting its future on its proprietary BiTAC technology, a strategic pivot that sharpens its focus amid a volatile market for cancer therapies.

Novartis's acquisition of Myricx Bio isn't just a deal. It's a story of academic grit, venture capital vision, and a new blueprint for patient-centric cancer therapy.

Revolution Medicines' zoldonrasib delivers high response rates in trials for RAS G12D pancreatic cancer, offering a beacon of hope against a lethal disease.

Molecular Partners and Orano Med begin human trials for a novel radiopharmaceutical, hoping to unlock a new front against small cell lung cancer.